The Latest

  • An illustration for BioPharma Dive's deals database
    Image attribution tooltip
    Adeline Kon/BioPharma Dive
    Image attribution tooltip
    Deep Dive

    Biotech M&A is accelerating. Track the deals that are happening here.

    AbbVie’s $10.9 billion acquisition of Apogee Therapeutics is the year’s second-largest biotech buyout and the company’s biggest since its $63 billion takeover of Allergan in 2019.

    Updated June 22, 2026
  • A conceptual illustration of neural activity in a brain.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    Brain drug revival

    To Wall Street, psychedelics biotechs are more teammates than rivals

    Some analysts argue that, even for competitors, a big clinical trial win for Definium Therapeutics helps validate the psychedelic field and “bring it even further into the mainstream.”

  • A bottle of pills lays on top of a sheet of $100 bills.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    Theravance, after clinical setbacks, agrees to $929M buyout

    The acquisition by royalty management company Zymeworks follows a "strategic review" triggered by the failure of a drug for a type of low blood pressure.

  • Modern glass window office building facade with the logo of Bristol Myers Squibb.
    Image attribution tooltip
    Alamy
    Image attribution tooltip

    Beeline ups its Series A round for immune drug work

    The company, which was built by Bain Capital, has now raised more than $426 million in its quest to advance a portfolio of Bristol Myers drugs.

  • Physicians, researchers and healthcare professionals attend ASCO's annual Meeting on June 2, 2023 in Chicago.
    Image attribution tooltip

    ASCO / Nick Agro

    Image attribution tooltip

    The top biopharma conferences remaining in 2026

    Medical meetings often feature important clinical trial results, making them barometers of biotech and pharma companies’ research progress. Here’s a list of conferences to watch the rest of 2026.

    Updated June 25, 2026
  • The Nasdaq MarketSite is seen on October 12, 2022 in New York City.
    Image attribution tooltip
    Michael M. Santiago via Getty Images
    Image attribution tooltip
    Q&A // Emerging biotech

    How Kardigan spun deal leftovers into a $400M IPO

    CEO Tassos Gianakakos said having late-stage assets and a team fortified at MyoKardia really resonated with investors. SpaceX's huge public offering didn't hurt either.

  • A stack of newspapers are seen against a blue background.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    News roundup

    FDA accepts Replimune filing; Merck KGaA drops $11B on life sciences services

    Replimune’s application is the latest example of changing attitudes at the FDA. Elsewhere, Revolution Medicines outlined more RAS-blocking data and a Definium stock offering brought in $800 million.

  • Pill gavel
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    On second try, Acadia drug gets nod from European regulators

    The influential CHMP committee also threw its support behind more than a dozen other medicines while recommending the marketing authorization for Tavneos be revoked.

  • A sign for the Food And Drug Administration is seen outside of the headquarters on July 20, 2020 in White Oak, Maryland.
    Image attribution tooltip
    Sarah Silbiger via Getty Images
    Image attribution tooltip

    Ionis, with new FDA nod, hits a ‘commercial inflection point’

    Historically seen as a "platform monetization story," according to one analyst, Ionis now has a potential multibillion-dollar medicine in Tryngolza, which secured expanded approval Wednesday.

  • A thumbnail illustration for BioPharma Dive's IPO tracker
    Image attribution tooltip
    Adeline Kon/BioPharma Dive
    Image attribution tooltip
    Deep Dive // IPO window

    Biotech IPOs are the industry’s lifeblood. Track how they’re performing.

    This year’s IPO class has already accounted for five of the six largest new biotech stock offerings since the start of 2022, according to BioPharma Dive data.

    Updated June 17, 2026
  • Wall street sign in New York City with New York Stock Exchange background
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    Remix to go public in reverse merger with once high-flying Passage Bio

    The transaction marks the latest turn in the fortunes of Passage Bio, one of the companies started by gene therapy pioneer Jim Wilson.

  • A sign spelling Novartis hangs on the side of a building.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    Antares gets $105M from Novartis for new cancer drugs

    Adam Friedman, CEO of the Scorpion Therapeutics spinout, said the deal helps both companies accelerate research "faster than either of us could alone."

  • A closeup of an eye with light reflecting off of it.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    Emerging biotech

    Ollin refuels with $330M to back pivotal tests of Vabysmo challenger

    One of the year’s largest venture funding rounds comes just after a head-to-head study showed Ollin’s drug — licensed from a China-based developer — had certain advantages over Roche’s eye treatment.

  • A stylized illustration of test tubes in front of a red line on a chart going up and to the right.
    Image attribution tooltip
    Adeline Kon/BioPharma Dive/BioPharma Dive
    Image attribution tooltip
    Deep Dive // Emerging biotech

    Biotech startups are built on venture capital. Track funding rounds here.

    Immune drugmakers carried the majority of venture financing in the second half of June, bringing in $608 million in total across five companies, according to BioPharma Dive data.

    Updated an hour ago
  • A micrograph image of influenza A virus.
    Image attribution tooltip
    NIAID. (2023). "Influenza A virus" [Micrograph]. Retrieved from Flickr.
    Image attribution tooltip
    Emerging biotech

    Investors pour $115M into RQ Bio in search of a preventive flu drug

    The startup claims to have a “differentiated” antibody that can provide long-lasting protection against a variety of influenza strains.

  • A stack of newspapers are seen against a blue background.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    News roundup

    Sangamo holds a bankruptcy sale; VCs back a China-linked Beam competitor

    Eli Lilly and Astellas will be the lead bidders at an auction for Sangamo assets. Elsewhere, an investor syndicate committed $230 million to a gene editing startup and Merck KGaA struck a “build-to-buy” deal.

  • FDA magnifying glass
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    China competition

    HHS, responding to China’s rise, moves to fast-track early drug research

    A series of newly planned reforms are designed to entice companies to start early trials in the U.S. rather than overseas.

  • A technician wearing a blue mask works in a laboratory.
    Image attribution tooltip
    Kevin Frayer via Getty Images
    Image attribution tooltip
    China competition

    Drugs from China are reshaping biotech. Track the licensing deals here.

    AstraZeneca, Pfizer and Bristol Myers Squibb have each allocated more than $16 billion to collaborations with Chinese drugmakers since the start of 2025 — surpassing all of their pharmaceutical peers over that timeframe.

    Updated June 1, 2026
  • Pfizer's logo cast in metal.
    Image attribution tooltip
    Jeenah Moon via Getty Images
    Image attribution tooltip

    Pfizer drug acquired in Seagen deal disappoints in lung cancer study

    The setback dims the outlook for a medicine Pfizer sees as an important contributor going forward, though some analysts are optimistic about the drug’s chances in another trial.

  • The AbbVie logo is prominently displayed on the facade of a sleek, contemporary building surrounded by a clear blue sky.
    Image attribution tooltip
    Alamy
    Image attribution tooltip

    AbbVie to acquire Apogee, staking nearly $11B on long-acting autoimmune drugs

    AbbVie’s largest deal in more than half a decade adds a group of immune disease medications — among them a Dupixent competitor — the company believes to have “mega-blockbuster” sales potential.

  • A stack of newspapers are seen against a blue background.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    News roundup

    Sanofi swaps R&D leaders; Merck’s Prometheus deal pays dividends

    Houman Ashrafian is leaving Sanofi to pursue a new opportunity. Elsewhere, one of Merck’s prized immune drugs succeeded in a pivotal study and a psychedelics biotech’s shares surged.

  • A sign for the FDA is displayed outside the agency's headquarters in Silver Spring, Maryland.
    Image attribution tooltip
    Sarah Silbiger via Getty Images
    Image attribution tooltip

    Regenxbio to resubmit gene therapy as FDA backtracks on another drug rejection

    The agency took another step toward clearing a backlog of Makary-era rejections that appeared to contradict earlier agreements with drugmakers.

  • A woman's hands over her abdomen.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    Startup launches

    Bionyra brings in $165M for next-generation immune drugs

    The biotech, co-founded by Sofinnova Partners and a former Sanofi immunology R&D head, is testing new biologics against common immune conditions.

  • Medicine pill on 100 dollar banknote background
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    Hospitals irate after Eli Lilly follows through on 340B ultimatum

    The drugmaker stopped paying 340B discounts to hospitals that didn’t comply with its new paperwork requirements late last week. Hospitals are urging HRSA to step in.

  • A Moderna logo is displayed on a building in Cambridge, Massachusetts, on Sept. 5, 2024.
    Image attribution tooltip
    Jacob Bell/BioPharma Dive
    Image attribution tooltip
    Vaccines

    Moderna flu vaccine wins unanimous support from FDA panel

    The endorsement of an advisory committee positions Moderna to complete a dramatic turnaround for a shot the FDA declined to review earlier this year.